Paris, November 18th, 2021
This transaction was arranged by Caisse d’Epargne Grand-Est Europe, advised by De Gaulle Fleurance & Associés.
Through this financing, BIOSYNEX plans to secure the Group’s general needs and pursue its external acquisitions with the ambition of becoming the European leader in the field of rapid POC (“Point Of Care”) diagnostics.
These acquisitions are intended to build up a portfolio of synergistic and complementary technologies in molecular biology and in point-of-care. In addition, the Group intends to accelerate its international development through the consolidation of its distributors and the creation of new subsidiaries.
De Gaulle Fleurance & Associés (May Jarjour, Partner, and Vahan Guevorkian, Lawyer) advised La Caisse d’Epargne Grand-Est Europe (Mireille Maury) on this transaction.
Energy transition of the territories: De Gaulle Fleurance has advised a consortium in the setting up of a strategic partnership
PRESSE RELEASE CNR, Banque des Territoires and the regional banks of Crédit Agricol...
Banking and finance: Cyril Tour joins De Gaulle Fleurance as a partner
PRESSE RELEASE With the arrival of Cyril Tour, De Gaulle Fleurance strengthens its ...
